Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.

Trial Details

NCT ID
NCT07140900
Phase
PHASE1
Sponsor
Amgen
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Xaluritamig
  • Darolutamide
  • Abiraterone
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Participants must have histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate. Mixed histologies (eg, adenoc…
  • Participants must have at the time of diagnosis:
  • De novo (synchronous) mHSPC, defined as metastatic disease with no prior diagnosis of localized prostate cancer, AND started ADT (LHRH agonist/anta…
  • Participants must have at the time of diagnosis:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →